In a report released yesterday, Steven Seedhouse from Raymond James maintained a Buy rating on Viking Therapeutics (VKTX), with a price target of $27.00. The company’s shares closed last Wednesday at $6.36.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 10.4% and a 49.7% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $17.29, a 178.0% upside from current levels. In a report released today, Chardan Capital also maintained a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.09 and a one-year low of $5.23. Currently, Viking Therapeutics has an average volume of 1.24M.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VKTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
